Osteoporosis in postmenopausal women & men at increased risk of fracture. Osteoporosis associated w/ sustained systemic glucocorticoid therapy in women & men at increased risk for fracture.
View Forteo overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. Preexisting hypercalcemia. Metabolic bone diseases (eg, hyperparathyroidism & Paget's bone disease) other than primary osteoporosis or glucocorticoid-induced osteoporosis. Unexplained elevations of alkaline phosphatase. Prior external beam or implant radiation therapy to the skeleton. Skeletal malignancies or bone metastases. Severe renal impairment. Pregnancy & lactation.
Transient elevations of serum Ca conc; increased urinary Ca excretion. Increased osteosarcoma incidence w/ long-term administration. Active or recent urolithiasis, episodes of transient orthostatic hypotension. May affect ability to drive & use machines. Moderate renal impairment. Hepatic impairment. Women of childbearing potential should use effective contraception methods; premenopausal women. Not to be used in childn & adolescents <18 yr or young adult w/ open epiphyses.
Sign Out
 20 mcg_80 microlitre68cc9830-3483-43fc-8813-9faa000a0deb.GIF)
